Share
Market Research Report

GENOMIC CANCER TESTING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Segmentation
  • By Test TypeGenomic Profiling Tests · Liquid Biopsy Tests · Companion Diagnostic Tests · Pharmacogenomic Tests · Hereditary Cancer Tests · Other specialized genomic tests
  • By Cancer TypeBreast Cancer · Lung Cancer · Colorectal Cancer · Prostate Cancer · Ovarian Cancer · Melanoma · Leukemia · Lymphoma · Other specific cancer types
  • By TechnologyNext-Generation Sequencing · Polymerase Chain Reaction · Fluorescence In Situ Hybridization · Microarray · Immunohistochemistry · Other genomic testing technologies
  • By End-UserHospitals · Diagnostic Laboratories · Academic and Research Institutions · Cancer Centers · Other healthcare providers
  • By Biomarker TypeGenetic Biomarkers · Protein Biomarkers · Molecular Biomarkers · Epigenetic Biomarkers
  • By Service ProviderDiagnostic Laboratories · Biotechnology Companies · Pharmaceutical Companies · Contract Research Organizations
  • By ApplicationTargeted Therapy Selection · Disease Monitoring · Prognostic Testing · Companion Diagnostics · Risk Assessment · Pharmacogenomic Testing
  • By Testing SettingIn-House Testing · Outsourced Testing
  • By GeographyNorth America · Latin America · Europe · Asia Pacific · Middle East & Africa
  • Published In29 Apr 2026
  • Report CodeCMI5914
  • Pages250+
  • FormatsExcel and PDF
  • Base Year2025
  • Estimated Year2026
  • Historical Range2020 - 2024
  • Forecast Period2026-2033

Global Genomic Cancer Testing Market Segmentation:

  • By Test Type (Revenue, USD Bn, 2021 - 2033)

    • Genomic Profiling Tests
    •  Liquid Biopsy Tests
    •  Companion Diagnostic Tests
    •  Pharmacogenomic Tests
    •  Hereditary Cancer Tests
    •  Other specialized genomic tests
  • By Cancer Type (Revenue, USD Bn, 2021 - 2033)

    • Breast Cancer
    •  Lung Cancer
    •  Colorectal Cancer
    •  Prostate Cancer
    •  Ovarian Cancer
    •  Melanoma
    •  Leukemia
    •  Lymphoma
    •  Other specific cancer types
  • By Technology (Revenue, USD Bn, 2021 - 2033)

    • Next-Generation Sequencing (NGS)
    •  Polymerase Chain Reaction (PCR)
    •  Fluorescence In Situ Hybridization (FISH)
    •  Microarray
    •  Immunohistochemistry (IHC)
    •  Other genomic testing technologies
  • By End User (Revenue, USD Bn, 2021 - 2033)

    • Hospitals
    • Diagnostic Laboratories
    •  Academic and Research Institutions
    •  Cancer Centers
    •  Other healthcare providers
  • By Biomarker Type (Revenue, USD Bn, 2021 - 2033)

    • Genetic Biomarkers
    •  Protein Biomarkers
    •  Molecular Biomarkers
    •  Epigenetic Biomarkers
  • By Service Provider (Revenue, USD Bn, 2021 - 2033)

    • Diagnostic Laboratories
    •  Biotechnology Companies
    •  Pharmaceutical Companies
    •  Contract Research Organizations (CROs)
  • By Application (Revenue, USD Bn, 2021 - 2033)

    • Targeted Therapy Selection
    •  Disease Monitoring
    •  Prognostic Testing
    •  Companion Diagnostics
    • Risk Assessment
    •  Pharmacogenomic Testing
  • By Testing Setting (Revenue, USD Bn, 2021 - 2033)

    • In-House Testing
    • Outsourced Testing
  • Regional Insights (Revenue, USD Bn, 2021 - 2033)

    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa